Ethinyl estradiol-to-desogestrel ratio impacts endothelial function in young women

Contraception

Volumn 79, Issue 1, 2009, Pages 41-49

  Meendering, Jessica R ^a   Torgrimson, Britta N ^a   Miller, Nicole P ^a   Kaplan, Paul F ^a,b   Minson, Christopher T ^a  

^a UNIVERSITY OF OREGON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Birth control pills; Cardiovascular risk; Estrogen; Flow mediated dilation; Progestin

Indexed keywords

APRI; CHOLESTEROL; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN; KARIVA; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; HUMAN; LOW DRUG DOSE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DESOGESTREL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ETHINYL ESTRADIOL; FEMALE; HUMANS; RISK FACTORS; VASODILATION; YOUNG ADULT;

EID: 56549117585     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2008.07.025     Document Type: Article

References (55)

1. Rosenfield A. Oral and intrauterine contraception: a 1978 risk assessment. Am J Obstet Gynecol 132 (1978) 92-106
2. Baillargeon J.P., McClish D.K., Essah P.A., and Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90 (2005) 3863-3870
3. Burkman R.T. Oral contraceptives: current status. Clin Obstet Gynecol 44 (2001) 62-72
4. Burkman R.T., Collins J.A., Shulman L.P., and Williams J.K. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 185 (2001) S4-S12
5. Carr B.R., and Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception 55 (1997) 267-272
6. Dalen J.E., and Hickler R.B. Oral contraceptives and cardiovascular disease. Am Heart J 101 (1981) 626-639
7. Heinemann L.A. Emerging evidence on oral contraceptives and arterial disease. Contraception 62 Suppl (2000) 29S-36S [discussion 7S-8S]
8. Böttiger L.E., Boman G., Eklund G., and Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1 (1980) 1097-1101
9. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., and Lundin F.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133 (1991) 32-37
10. Vessey M., Mant D., Smith A., and Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ (Clin Res Ed) 292 (1986) 526
11. Cid M.C., Schnaper H.W., and Kleinman H.K. Estrogens and the vascular endothelium. Ann N Y Acad Sci 966 (2002) 143-157
12. Mendelsohn M.E. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 89 (2002) 12E-18E
13. Gilligan D.M., Badar D.M., Panza J.A., Quyyumi A.A., and Cannon III R.O. Acute vascular effects of estrogen in postmenopausal women. Circulation 90 (1994) 786-791
14. Farhat M.Y., Lavigne M.C., and Ramwell P.W. The vascular protective effects of estrogen. FASEB J 10 (1996) 615-624
15. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
16. Kawano H., Motoyama T., Kugiyama K., et al. Menstrual cyclic variation of endothelium-dependent vasodilation of the brachial artery: possible role of estrogen and nitric oxide. Proc Assoc Am Physicians 108 (1996) 473-480
17. Hashimoto M., Akishita M., Eto M., et al. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92 (1995) 3431-3435
18. English J.L., Jacobs L.O., Green G., and Andrews T.C. Effect of the menstrual cycle on endothelium-dependent vasodilation of the brachial artery in normal young women. Am J Cardiol 82 (1998) 256-258
19. Reis S.E., Gloth S.T., Blumenthal R.S., Resar J.R., Zacur H.A., and Gerstenblith G. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 89 (1994) 52-60
20. Faludi A.A., Aldrighi J.M., Bertolami M.C., et al. Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. Atherosclerosis 177 (2004) 89-96
21. Kawano H, Motoyama T, Hirai N, et al. Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. Am J Cardiol 2001;87:238-40, A9.
22. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273 (1995) 199-208
23. Wakatsuki A., Okatani Y., Ikenoue N., and Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 104 (2001) 1773-1778
24. Benagiano G., Primiero F.M., and Farris M. Clinical profile of contraceptive progestins. Eur J Clin Chem Clin Biochem 9 (2004) 182-193
25. Hammond G.L., Rabe T., and Wagner J.D. Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Am J Obstet Gynecol 185 2 Suppl (2001) S24-S31
26. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 21 (2004) 865-883
27. Stanczyk F.Z. All progestins are not created equal. Steroids 68 (2003) 879-890
28. Squadrito F., Altavilla D., Crisafulli A., et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med 114 (2003) 470-476
29. van Rooijen M., von Schoultz B., Silveira A., Hamsten A., and Bremme K. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am J Obstet Gynecol 186 (2002) 44-48
30. Ganz P. Vasomotor and vascular effects of hormone replacement therapy. Am J Cardiol 90 (2002) 11F-16F
31. Joannides R., Haefeli W.E., Linder L., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91 (1995) 1314-1319
32. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
33. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
34. Torgrimson B.T., Meendering J.R., Kaplan P.F., and Minson C.T. Endothelial function across an oral contraceptive cycle in women using levonorgestrel and ethinyl estradiol. Am J Physiol Heart Circ Physiol 288 (2007) H103-H110
35. Woodman R.J., Playford D.A., Watts G.F., et al. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol 91 (2001) 929-937
36. Pyke K.E., Dwyer E.M., and Tschakovsky M.E. Impact of controlling shear rate on flow-mediated dilation responses in the brachial artery of humans. J Appl Physiol 97 (2004) 499-508
37. Pyke K.E., and Tschakovsky M.E. The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol 568 (2005) 357-369
38. Pyke K.E., and Tschakovsky M.E. Peak vs. total reactive hyperemia: which determines the magnitude of flow-mediated dilation?. J Appl Physiol 102 (2007) 1510-1519
39. Berry K.L., Skyrme-Jones R.A., and Meredith I.T. Occlusion cuff position is an important determinant of the time course and magnitude of human brachial artery after different circulatory occlusion conditions. Clin Sci 99 (2000) 261-267
40. Naylor L.H., Weisbrod C.J., O'Driscoll G., and Green D.J. Measuring peripheral resistance and conduit arterial structure in humans using Doppler ultrasound. J Appl Physiol 98 (2005) 2311-2315
41. Lammers P., Blumenthal P.D., and Huggins G.R. Developments in contraception: a comprehensive review of desogen (desogestrel and ethinyl estradiol). Contraception 57 Suppl (1998) 1S-27S
42. Stone S.C. Desogestrel. Clin Obstet Gynecol 38 (1995) 821-828
43. Vogel R.A. Cholesterol lowering and endothelial function. Am J Med 107 (1999) 479-487
44. Vogel R.A., Corretti M.C., and Gellman J. Cholesterol, cholesterol lowering, and endothelial function. Prog Cardiovasc Dis 41 (1998) 117-136
45. Wilkinson I.B., and Cockcroft J.R. Cholesterol, endothelial function and cardiovascular disease. Curr Opin Lipidol 9 (1998) 237-242
46. Fotherby K. Oral contraceptives, lipids and cardiovascular disease. Contraception 31 (1985) 367-394
47. Hennekens C.H., Evans D.A., Castelli W.P., Taylor J.O., Rosner B., and Kass E.H. Oral contraceptive use and fasting triglyceride, plasma cholesterol and HDL cholesterol. Circulation 60 (1979) 486-489
48. Knopp R.H., Walden C.E., Wahl P.W., et al. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglycerides and cholesterol in an adult female population: relationships to estrogen and progestin potency. J Clin Endocrinol Metab 53 (1981) 1123-1132
49. Nessa A., Latif S.A., and Uddin M. Effects of low dose oral contraceptives on serum total cholesterol, TAG, HDL-C & LDL-C levels in contraceptive users. Mymensingh Med J 14 (2005) 26-28
50. Lobo R.A., Skinner J.B., Lippman J.S., and Cirillo S.J. Plasma lipids and desogestrel and ethinyl estradiol: a meta analysis. Fertil Steril 65 (1996) 1100-1109
51. Penttila I.M., Bergink E.W., Holma P., et al. Serum lipids and proteins during treatment with a new oral contraceptive combination containing desogestrel. Eur J Obstet Gynecol Reprod Biol 16 (1983) 275-281
52. Akerlund M., Alstrom E., Hogstedt S., and Nabrink M. Oral contraceptive tablets containing 20 and 30 μg of ethinyl estradiol with 150 μg desogestrel: their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand 73 (1994) 136-143
53. Houghton B.L., Holowatz L.A., and Minson C.T. Influence of progestin bioactivity on cutaneous vascular responses to passive heating. Med Sci Sports Exerc 37 (2005) 45-51
54. Meendering J.R., Torgrimson B.N., Houghton B.L., Halliwill J.R., and Minson C.T. Effects of menstrual cycle and oral contraceptive use on calf venous compliance. Am J Physiol Heart Circ Physiol 288 (2005) H103-H110
55. John S., Jacobi J., Schlaich M.P., Delles C., and Schmieder R.E. Effects of oral contraceptives on vascular endothelium in premenopausal women. Am J Obstet Gynecol 183 (2000) 28-33